Skip to main content
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc.

Track MDGL — free
$379.10 -17.64 (-4.45%) At close · Nov 20
Market Cap
$8.81B
Shares
23.23M
Volume · Nov 20 327.92K Avg daily vol (3M) 367.24K

Price & Indicators

 

Key stats

Close
$379.10
Fri 20 Nov
Open
$396.74
Fri 20 Nov
Average volume, 30 days
521K
shares a session
Short interest
2.1M
9.2% of shares · 7.6 days to cover
Day range
$377.90$399.43
Open $396.74 Close $379.10
52-week closing range
$379.10$602.83
Close $379.10 37.1% under the high
Short volume, last session
39%
Last earnings
Nov 3, 2026
Latest filing
10-Q · Nov 3
Price history
Jan 2020 to Nov 2026

Up next

Feb 18, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 17
Investor event
Maestro Nash Outcomes Readout Now Expected Late 2027

Madrigal Pharmaceuticals said the Maestro Nash outcomes readout is now expected in late 2027 and that it can start an even larger trial. The company reported $431 million for the third quarter and $1.1 billion in sales through Q3. The market is growing 30% this year.

5 source passages
Instead of saying, you know, all of 2027's potential, we started saying late 2027. we also have this opportunity now where we can start an even larger trial We recently reported $431 million for the third quarter. That's $1.1 billion in sales through Q3. We have a market that is growing 30% this year Open the document at this passage
Nov 3
Earnings call
Sales reach $431.3 million as company posts first profitable quarter

Madrigal Pharmaceuticals, Inc. reported third-quarter 2026 net sales of $431.3 million, up 50% year-over-year, and its first profitable quarter, with net income of $55.4 million.

3 source passages
Third quarter of 2026, net sales were $431.3 million, up 50% year-over-year, with year-to-date net sales of $1.1 billion. The third quarter marked another important milestone for Madrigal, our first quarter profitability. We reported net income of $55.4 million compared to a net loss of $114.2 million. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Rezdiffra revenue rises as quarterly net income turns positive

Madrigal Pharmaceuticals recorded $431.3 million in net product revenue for the three months ended September 30, 2026, versus $287.3 million in the corresponding period in 2025, and reported $55.4 million in net income.

Revenue $431.27M ▲ 50.1% Net income $55.44M Diluted EPS $1.83
Read from the MD&A section
3 source passages
About Madrigal Pharmaceuticals, Inc. We recorded $431.3 million of product revenue, net for the three months ended September 30, 2026, compared to $287.3 million in the corresponding period in 2025. The increase was driven by increased demand for Rezdiffra in the United States in 2026. Although we generated net income of $55.4 million for the three months ended September 30, 2026, we have incurred losses since inception Open the document at this passage
Nov 3
Current report 8-K
Rezdiffra nets $431.3 million, marking first profitable quarter

Madrigal Pharmaceuticals reported third-quarter 2026 Rezdiffra net sales of $431.3 million, up 50% year over year, and achieved its first profitable quarter with net income of $55.4 million; year-to-date Rezdiffra net sales reached $1.1 billion.

Financial results
4 source passages
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates Third-quarter 2026 Rezdiffra® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion Net Income: Third-quarter 2026 net income was $55.4 million, or $1.90 per basic share and $1.83 per diluted share, compared to a net loss of $114.2 million, or $4.01 per basic and diluted share, in the comparable prior year period. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.43B
Trailing 12 months
Net income (TTM)
−$155.46M
Trailing 12 months
Revenue growth YoY
+50.1%
Year over year
Operating margin
-10.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$173.37M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.3%
Year over year · more shares
Price change (1Y)
-30.1%
Trailing year
Short interest
9.2%
Latest settlement · 7.6 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026
Q2 FY26

TL;DR. Madrigal delivered Q2 2026 Rezdiffra net sales of $364.3 million (+71% YoY) with over 49,000 patients on therapy, added three new resmetirom patents (including an F4c patent extending protection into 2042), advanced its oral GLP-1 MGL-2086 into Phase 1, and confirmed it is comfortable with consensus quarterly growth rates for the remainder of 2026; however, operating expenses rose sharply and net loss widened to $57.9 million.

Bullish
  • + Rezdiffra Q2 2026 net sales grew 71% year-over-year to $364.3 million, with more than 49,000 patients on therapy (over 50,000 reached earlier in July).
  • + Strengthened IP estate with three new resmetirom patents, including an F4c use patent extending protection into 2042.
  • + MGL-2086 oral GLP-1 advanced into the clinic with Phase 1 single ascending dose dosing initiated in June 2026, supporting Rezdiffra combination strategy.
  • + Management is comfortable with consensus quarterly net sales growth rates for Q3 and Q4 2026.
  • + Trailing 12-month Rezdiffra net sales reached nearly $1.3 billion, reinforcing mega-blockbuster potential, with the addressable F2-F3 specialist market growing ~50% in two years to 460,000 patients.
Bearish
  • − Cost of sales surged to $40.0 million from $9.1 million, driven by higher Roche royalties and a work-in-process inventory write-down.
  • − R&D expenses nearly doubled to $91.2 million from $54.1 million, with SG&A expenses rising to $289.4 million from $196.9 million as commercial investment scaled.
  • − Cash, cash equivalents, restricted cash and marketable securities declined to $838.9 million at June 30, 2026 from $988.6 million at year-end 2025.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Fair Quant / Vol High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −18%
below
RSI (14) 26
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −16%
trailing
YTD return −35%
this year
Relative strength −7%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $462 › 200d $494 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +78 funds added
Insider flow Accumulating
Net +$35.0M over 90 days · 0% sells
Short interest Falling
9.20% of shares out · ▼ -2.6% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
448 holders — near 3-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Fair
EPS growth +41%
Y/Y
Free cash flow $-190.0M
Balance sheet $141.2M
net debt
Quant / Vol
risk profile
High
Volatility 43%
annualized · 1-yr
Max drawdown −37%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
26 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $462 › 200d $494 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +78 funds added
Insider flow Accumulating
Net +$35.0M over 90 days · 0% sells
Short interest Falling
9.20% of shares out · ▼ -2.6% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
448 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $379 Now $379 · 0% Range high $603
vs 200-day avg -23% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Addressable U.S. F2-F3 MASH patients 530,000 through June 30, 2026 —
Cash, cash equivalents, restricted cash and marketable securities $961.8M as of Sept. 30, 2026 —
Non-cash stock-based compensation expense in operating expenses $38.9M Third-quarter 2026 —
Rezdiffra net sales $431.3M third-quarter 2026 —
Rezdiffra year-to-date net sales $1.1B year-to-date 2026 —
Patients on Rezdiffra 49,000 As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MDGL
Madrigal Pharmaceuticals, Inc.
this stock
$8.81B -34.9% +432.1% — 9.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
448
% held
94.9%
Net QoQ
-1.6M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
392
View
Short & Settlement
Short Interest Falling
Shares short
2.1M
Days to cover
7.6d
Change
-58.1K sh
View
Short Volume
Short vol %
39%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
22
Value
$10.5K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
49.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$35.0M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Apr 10, 2023
View
Financials
Financials
Revenue (FY)
$958.4M
Net income (FY)
$-288.3M
EPS diluted
$-10.15
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
19

Madrigal Pharmaceuticals said the Maestro Nash outcomes readout is now expected in late 2027 and that it can start an even larger trial. The company reported $431 million for the third quarter and $1.1 billion in sales through Q3. The market is growing 30% this year.

View
Proposed Sales
Value
$430.9K
Shares
1.1K
Filed
Nov 6, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Madrigal Pharmaceuticals Announce…
Published
Nov 13, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
MDGL -11.3% -12.7% -16.3% -11.9% -34.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -2.7% -3.5% -7.1% -3.2% -36.1%
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 432 filings 393 filers Visit website Investor relations